摘要
目的:研究回生口服液对晚期非小细胞肺癌患者血浆纤维蛋白原和血小板水平的影响。方法:选取2011年1月至2013年7月已被收治的112例晚期非小细胞肺癌患者按照知情同意原则随机分为治疗组(60例)和对照组(52例)两组,治疗组在支持、对症治疗的基础上口服回生口服液治疗,对照组仅给予支持、对症治疗,4周后观察两组患者经两种不同的治疗方案治疗后患者血浆纤维蛋白原及血小板水平变化。结果:治疗组经给药治疗后血浆纤维蛋白原及血小板水平与治疗前相近,差异均无统计学意义(P>0.05);对照组经治疗后血浆纤维蛋白原及血小板水平较治疗前高,差异均有统计学意义(P<0.05);治疗组给药治疗后血浆纤维蛋白原及血小板水平均较对照组低,差异均有统计学意义(P<0.05)。结论:回生口服液可能是通过降低血浆纤维蛋白原及血小板的含量从而改善晚期非小细胞肺癌患者的血液高凝状态。
Objective： To stdudy the effect of Huishengkoufuye on plasma fibrinogen and blood platelet in patients with advanced non-small cell lung cancer. Methods： 112 cases of advanced non-small cell lung disease patient who had been treated in our hospital from January 2011 to July 2013, divided into two groups randomly, the treat group （60 cases） and the control group （52 cases）, the treat group gave Huishengkoufuye to treat patients on the basis of support and symptomatic treatment, while the control group only gave support and symptomatic treatment. After four weeks ,observed the change of plasma fibrinogen and blood platelet levels of the two groups after two different treatment methods. Results： After medicine treatment ,the level of plasma fibrinogen and blood platelet of the treat group was similar to before ,the difference has no statistically significance （P〉0.05）; the level of plasma fibrinogen and blood platelet of the control group was higher than before, the difference has statistically significance （P〈0.05）; the level of plasma fibrinogen and blood platelet of treat group was lower than control group, the difference has statistically significance （P〈0.05）. Conclusions： Huishengkoufuye might improve the state of blood hypercoagulability by decrease the content of plasma fibrinogen and blood p latelet.
出处
《现代生物医学进展》
CAS
2014年第3期550-552,563,共4页
Progress in Modern Biomedicine
关键词
回生口服液
晚期非小细胞肺癌
纤维蛋白原
血小板
Huishengkoufuye
Advanced Non-small Cell Lung Cancer
Plasma Fibrinogen
Blood Platelet
